All In Biotech

Drug Trial Radar · NCT07449754

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

A Phase 2, Multicenter, Single-Arm Study of Belvarafenib (HM95573) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Feb 12, 2026

Primary completion

Sep 2029

Study completion Mar 2030

Sponsor

Sponsor type
Industry
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 open-label, multicenter, single-arm study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations. The study plans to assess ORR, DCR, DOR, TTP, PFS, OS and safety of the participating subjects. Treatment cycles for all subjects will be 28 days in duration and Belvarafenib and Cobimetinib will be administered orally in combination.

Conditions

  • Advanced or Metastatic Melanoma

Interventions

  • BelvarafenibDrug

    Belvarafenib will be taken twice daily (BID) on Days 1-28 of each cycle

  • CobimetinibCombination product

    Cobimetinib will be taken on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of each cycle (three times weekly, TIW), followed by a drug holiday through Day 28

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Throughout the study until disease progression or death whichever occurs first (up to approximately 3 years)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Dong-A University Medical Center

    Busan, South Korea · Recruiting

  • Kyungpook National University Chilgok Hospital

    Daegu, South Korea · Not yet recruiting

  • Chungnam National University Hospital

    Daejeon, South Korea · Not yet recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Not yet recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Korea University Guro Hospital

    Seoul, South Korea · Not yet recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Not yet recruiting

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeollanam-do, South Korea · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.